Hot! Delta and Omicron Mutated Strains are Available!
*Shipping time varies country by country, please quote for more detail.
Entry of Coronavirus into host cells is mediated by the trimeric transmembrane spike (S) glycoprotein (Fig. 1). S glycoprotein is surface-exposed and mediates entry into the host cells by binding to human angiotensin-converting enzyme 2 (ACE2), the SARS-CoV-2 receptor, which makes S glycoprotein the major target of neutralizing antibodies and the focus of therapeutic and vaccine design.
A model that simulates the infection of the SARS-CoV-2 is designed by replacing the envelope glycoprotein in the lentivirus vector with the S protein. Neutralizing antibodies blocking S protein (Fig. 2). and receptor binding could prevent the virus from infecting host cells. By detecting the luminescence of target cells, it is possible to screen or verify the activity of the neutralizing antibody.
ProBio provides not only assay service but also neutralization kit, meeting all your needs for both research and industry application.
-
Fig.1 Pseudovirus with S glycoprotein as the envelope protein
-
Fig.2 Neutralizing antibodies preventing the pseudovirus from entering host cells
Workflow of Neutralization Assay
Service Highlights
- Virus entry assay model:
A viral entry model, mimicking physiological entry mechanism. - Variants of SARS-CoV-2 available
Extensible system, SARS-CoV-1 and multiple variants available, including Omicron; customized variant available. - High specificity:
Ability to specifically screen drugs blocking pseudovirus entry. - High sensitivity:
S/N > 100, activities of different candidates can be clearly distinguished. - Fast delivery:
1-3 weeks to get results
Service Details
Starting materials- ≥ 100 μg neutralizing antibody for single dose screening, or ≥ 200 μg for dose-response assay
- supernatant with antibody ≥ 1 μg/mL, more than ≥ 500 μL (Optimization is needed for different culture media)
- Serum samples from immunized animals. Human samples should be tested with pseudovirus neutralization kit
- Small molecules, peptides or other candidate samples inhibiting virus entry
- Pseudovirus and target cells for infection are provided by ProBio
Delivery: Neutralization assay report
QC standard: S/N ≥ 100
Turnaround time: 1-3 weeks*
*TAT may extend due to the number of samples.Pseudovirus Neutralization Assay Kit
| Product | Cat. No. | name | Deliverable | TAT |
|---|---|---|---|---|
| Luciferase reporter kit | SC2087A | SARS-CoV-2 Pseudovirus Neutralization Assay kit_Luc reporter |
Components: |
Wild type:4 weeks Mutant type:Quote |
| SC2087B | SARS-CoV-2 D614G Pseudovirus Neutralization Assay kit_Luc reporter | |||
| SC2087C | SARS-CoV-2 V367F Pseudovirus Neutralization Assay kit _Luc reporter | |||
| SC2087D | SARS-CoV-2 W436R Pseudovirus Neutralization Assay kit _Luc reporter | |||
| SC2087E | SARS-CoV-2 D364Y Pseudovirus Neutralization Assay kit _Luc reporter | |||
| SC2087K | SARS-CoV-2 N501Y (B.1.1.7) Pseudovirus Neutralization Assay kit _Luc reporter | |||
| SC2087L | SARS-CoV-2 N501Y (B.1.351) Pseudovirus Neutralization Assay kit _Luc reporter | |||
| SC2087M | SARS-CoV-2 A222V Pseudovirus Neutralization Assay kit _Luc reporter | |||
| SC2087N | SARS-CoV-2 N439K Pseudovirus Neutralization Assay kit _Luc reporter | |||
| SC2087O | SARS-CoV-2 S477N Pseudovirus Neutralization Assay kit _Luc reporter | |||
| SC2087P | SARS-CoV-2 E484K Pseudovirus Neutralization Assay kit _Luc reporter | |||
| SC2087Q | SARS-CoV-2 Q677H Pseudovirus Neutralization Assay kit _Luc reporter | |||
| SC2087R | SARS-CoV-2 Y453F & Δ69-70 Pseudovirus Neutralization Assay kit _Luc reporter | |||
| SC2087S | SARS-CoV-2 N501Y Pseudovirus Neutralization Assay kit _Luc reporter | |||
| SC2087T | SARS-CoV-2 E484K & N501Y (B.1.1.7) Pseudovirus Neutralization Assay kit _Luc reporter | |||
| SC2087U | SARS-CoV-2 L452R (B.1.617.1) Pseudovirus Neutralization Assay kit _Luc reporter | |||
| SC2087V | SARS-CoV-2 L452R (B.1.617.2) Pseudovirus Neutralization Assay kit _Luc reporter | |||
| SC2087W | SARS-CoV-2 L452R (B.1.617.2-CDC, Delta) Pseudovirus Neutralization Assay kit _Luc reporter | |||
| SC2087X | SARS-CoV-2 L452R (AY.1, Delta plus) Pseudovirus Neutralization Assay kit _Luc reporter | |||
| SC2087Y | SARS-CoV-2 L452Q (C.37, Lambda) Pseudovirus Neutralization Assay kit _Luc reporter | |||
| SC2087Z | SARS-CoV-2 B.1.621 (Mu) Pseudovirus Neutralization Assay kit _Luc reporter | |||
| SC2087-027 | SARS-CoV-2 B.1.1.529 (Omicron) Pseudovirus Neutralization Assay kit _Luc reporter | |||
| GFP reporter kit | SC2087F | SARS-CoV-2 Pseudovirus Neutralization Assay kit _GFP reporter | ||
| SC2087G | SARS-CoV-2 D614G Pseudovirus Neutralization Assay kit _ GFP reporter | |||
| SC2087H | SARS-CoV-2 V367F Pseudovirus Neutralization Assay kit _ GFP reporter | |||
| SC2087I | SARS-CoV-2 W436R Pseudovirus Neutralization Assay kit _ GFP reporter | |||
| SC2087J | SARS-CoV-2 D364Y Pseudovirus Neutralization Assay kit _ GFP reporter |
* Components can be purchased separately. Please contact us.
Service Highlights
- Virus entry assay model:
A viral entry model, consistent with the physiological entry mechanism - Variants of SARS-CoV-2 available:
Extensible system, SARS-CoV-1 and multiple variants available; cutomized variants available - High specificity:
Ability to specifically screen drugs blocking pseudovirus entry - High sensitivity:
S/N as high as about 100, activities of different candidates can be clearly distinguished - Ready to use:
Save time on condition optimization - Free from sample degeneration:
Especially for serum samples
-
Pseudovirus neutralization assay
-
Live virus neutralization assay
Neutralization by ACE2-Fc
Figure 2. Positive control ACE2-Fc can effectively inhibit pseudovirus entry in a dose-dependent manner
Consistent IC50 in independent tests
Figure 3. Antibody candidates were screened for their ability to inhibit pseudovirus entry.
Neutralization by immunized mice serum
Figure 4. Immunized mouse serum can effectively inhibit pseudovirus entry
-
Figure 5. B.1.617.2 pseudovirus (Delta variant) was efficiently blocked by ACE2-Fc chimera proteins (left panel). RBD-63 mAb failed to inhibit the B.1.617.2 pseudovirus (Delta variant) infection (right panel).
-
-
Figure 6. Blocking Omicron pseudovirus entry into ACE2 overexpressing target cells by means of ACE2-Fc chimera protein.
Figure 1. Comparable IC50 values of live virus and pseudovirus neutralization assay using the same sample.
